Business, energy, technology, markets and global industry news from Business News Today

lysergide

PharmaDeviceNews lysergide
Representative image: Definium Therapeutics’ $805 million public offering strengthens its ability to advance DT120 ODT after positive Phase 3 depression trial results, while regulatory and commercial execution remain the next major tests.
Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

Read More
A clinician monitors a supervised treatment session as Definium Therapeutics advances DT120, a single-dose investigational therapy for major depressive disorder, following positive Phase 3 results. Representative image.
Pharma & Biotech

Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?

DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.

Read More